Riding on the increased sales of drugs both in the US and the domestic market, the companys gross turnover for the quarter stood at Rs 1707.7 crore, up 22% against Rs 1,405.5.
RLLs scrip, however, closed at Rs 430.20, down 0.3%, on the Bombay Stock Exchange as analysts expected the company to report EBIDTA marigns higher by 1,000 basis points. Ranbaxys EBIDTA, however, grew 900 basis points. For fiscal 2006, Ranbaxys net profit grew 97% at Rs 520.4 crore against Rs 264.2 crore in 2005. Consolidated sales for the year ended Deecember 31, 2006, stood at Rs 6,069.8 crore against Rs 5,188 crore during the corresponding period last fiscal.